4BIO Capital leads EUR 40 million seed round for Aptadir Therapeutics

• 4BIO Capital led a EUR 40 million seed financing in Aptadir Therapeutics to advance first-in-class demethylating RNA medicines.
• Aptadir develops DNMTs Interacting RNAs designed to reverse aberrant DNA methylation and reactivate silenced genes in genetic disorders and cancer.
• Proceeds will fund Aptadir’s RNA therapeutics pipeline, including CAP1-FMR1 for Fragile X Syndrome.
• EXTEND, Aptadir’s pre-seed investor, participated in the seed round alongside other new investors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BIO Partners LLP published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.